"CRLM is a major problem in the western hemisphere, just as primary liver cancer is in Asia Pacific," remarked Michael H. Tardugno, President & Chief Executive Officer of Celsion Corporation.  "We look forward to bringing ThermoDox to the market in the US, which will help address an estimated 300,000 cases of liver metastases, almost half of which come from colorectal cancer."

Celsion previously announced its plans to conduct a randomized Phase II CRLM study to further evaluate the efficacy of ThermoDox plus RFA.  This trial will be initiated later this year following the completion of enrollment in Celsion's pivotal Phase III HEAT trial for primary liver cancer trial.  "Local control in patients with liver metastasis is of interest to the medical community," noted Nicholas Borys, Celsion's Vice President and Chief Medical Officer.  "This study adds to the growing body of scientific data that ThermoDox may play an important role as an adjunct to liver tumor ablation."  

Dr. Ravikumar's oral presentation is available on Celsion's website at www.celsion/events.cfm.

SOURCE Celsion Corporation